valproic acid has been researched along with Cognitive Decline in 23 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the pharmacodynamic interaction study, seizures were induced using pentylenetetrazole (PTZ) (60 mg/kg, i." | 8.02 | Pharmacodynamic and pharmacokinetic interactions of hydroalcoholic leaf extract of Centella asiatica with valproate and phenytoin in experimental models of epilepsy in rats. ( Agarwal, A; Arora, R; Ganeshan N, S; Gupta, YK; Kaleekal, T; Kumar, R; Sarangi, SC, 2021) |
| "This study measured the serum carnitine levels in patients with epilepsy and determined the factors contributing to low carnitine levels." | 7.91 | Serum carnitine levels of children with epilepsy: Related factors including valproate. ( Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A, 2019) |
| "Our purpose was to evaluate the relationship between valproic acid (VPA)-induced hyperammonemia (HA) and the prevalence of minimal hepatic encephalopathy (MHE) cognitive impairment among psychiatric inpatients." | 7.83 | Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients. ( Doroudgar, S; La, AQ; Perry, PJ; Punia, S; Thomas, KL, 2016) |
| "Many studies show that the number of cognitive impairmentscan be reduced by antagonists of the histamine H3 receptor (H3R)." | 5.91 | Amelioration of cognition impairments in the valproic acid-induced animal model of autism by ciproxifan, a histamine H3-receptor antagonist. ( Esmaeilpour, K; Sepehri, G; Sheibani, V; Shekari, MA; Taheri, F, 2023) |
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 5.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| " In the pharmacodynamic interaction study, seizures were induced using pentylenetetrazole (PTZ) (60 mg/kg, i." | 4.02 | Pharmacodynamic and pharmacokinetic interactions of hydroalcoholic leaf extract of Centella asiatica with valproate and phenytoin in experimental models of epilepsy in rats. ( Agarwal, A; Arora, R; Ganeshan N, S; Gupta, YK; Kaleekal, T; Kumar, R; Sarangi, SC, 2021) |
| "This study measured the serum carnitine levels in patients with epilepsy and determined the factors contributing to low carnitine levels." | 3.91 | Serum carnitine levels of children with epilepsy: Related factors including valproate. ( Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A, 2019) |
| " He was found to have high anion gap metabolic acidosis with significantly elevated lactate along with an elevated osmolal gap and calcium oxalate crystals in his urine." | 3.85 | Two gaps too many, three clues too few? Do elevated osmolal and anion gaps with crystalluria always mean ethylene glycol poisoning? ( Abu Sitta, E; Gaddam, M; Kanzy, A; Velagapudi, RK, 2017) |
| "Our purpose was to evaluate the relationship between valproic acid (VPA)-induced hyperammonemia (HA) and the prevalence of minimal hepatic encephalopathy (MHE) cognitive impairment among psychiatric inpatients." | 3.83 | Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients. ( Doroudgar, S; La, AQ; Perry, PJ; Punia, S; Thomas, KL, 2016) |
| "Many studies show that the number of cognitive impairmentscan be reduced by antagonists of the histamine H3 receptor (H3R)." | 1.91 | Amelioration of cognition impairments in the valproic acid-induced animal model of autism by ciproxifan, a histamine H3-receptor antagonist. ( Esmaeilpour, K; Sepehri, G; Sheibani, V; Shekari, MA; Taheri, F, 2023) |
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 1.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| "A 69-year-old man with alcohol dependence and mild cognitive impairment (MCI) suffered from repeated tonic-clonic seizures." | 1.39 | Repeated seizures in an elderly patient with alcohol dependence and mild cognitive impairment. ( Araki, Y; Hatano, K; Ishii, N; Terao, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 14 (60.87) | 2.80 |
| Authors | Studies |
|---|---|
| Szczygieł-Pilut, EE | 1 |
| Zajączkowska-Dutkiewicz, A | 1 |
| Pilut, D | 1 |
| Dutkiewicz, J | 1 |
| Zhuo, C | 1 |
| Zhou, C | 1 |
| Tian, H | 1 |
| Li, Q | 1 |
| Chen, J | 1 |
| Yang, L | 1 |
| Zhang, Q | 1 |
| Li, R | 1 |
| Ma, X | 1 |
| Cai, Z | 1 |
| Chen, G | 1 |
| Xu, Y | 1 |
| Song, X | 1 |
| Kim, UJ | 1 |
| Hong, N | 1 |
| Ahn, JC | 1 |
| Zohny, SM | 1 |
| Habib, MZ | 1 |
| Mohamad, MI | 1 |
| Elayat, WM | 1 |
| Elhossiny, RM | 1 |
| El-Salam, MFA | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 1 |
| Taheri, F | 2 |
| Esmaeilpour, K | 2 |
| Sepehri, G | 1 |
| Sheibani, V | 2 |
| Shekari, MA | 1 |
| Joushi, S | 1 |
| Ebrahimi, MN | 1 |
| Taheri Zadeh, Z | 1 |
| Pigoni, A | 1 |
| Mandolini, GM | 1 |
| Delvecchio, G | 1 |
| Bressi, C | 1 |
| Soares, JC | 1 |
| Brambilla, P | 1 |
| Ibrahim, I | 1 |
| Tobar, S | 1 |
| Fathi, W | 1 |
| ElSayed, H | 1 |
| Yassein, A | 1 |
| Eissa, A | 1 |
| Elsheshtawy, E | 1 |
| Elboraei, H | 1 |
| Shahda, M | 1 |
| Elwasify, M | 1 |
| Ibrahim, A | 1 |
| Chen, K | 1 |
| Wood, J | 1 |
| Dickerson, F | 1 |
| Yolken, RH | 1 |
| El Chennawi, F | 1 |
| Gur, R | 2 |
| El Bahaey, W | 1 |
| Nimgaonkar, V | 1 |
| Mansour, H | 1 |
| Torres, IJ | 1 |
| Qian, H | 1 |
| Basivireddy, J | 1 |
| Chakrabarty, T | 1 |
| Wong, H | 1 |
| Lam, RW | 1 |
| Yatham, LN | 1 |
| Huber-Mollema, Y | 1 |
| van Iterson, L | 1 |
| Oort, FJ | 1 |
| Lindhout, D | 1 |
| Rodenburg, R | 1 |
| McKinnell, ZE | 1 |
| Maze, T | 1 |
| Ramos, A | 1 |
| Challans, B | 1 |
| Plakke, B | 1 |
| Kumar, R | 1 |
| Arora, R | 1 |
| Sarangi, SC | 1 |
| Ganeshan N, S | 1 |
| Agarwal, A | 1 |
| Kaleekal, T | 1 |
| Gupta, YK | 1 |
| Ryu, YK | 1 |
| Park, HY | 1 |
| Go, J | 1 |
| Choi, DH | 1 |
| Choi, YK | 1 |
| Rhee, M | 1 |
| Lee, CH | 1 |
| Kim, KS | 1 |
| Kavaye Kandeda, A | 1 |
| Okomolo Moto, FC | 1 |
| Mbomo Ayissi, RE | 1 |
| Omam Omam, JP | 1 |
| Ojong, L | 1 |
| Ngo Bum, E | 1 |
| Cho, SJ | 1 |
| Park, E | 1 |
| Baker, A | 1 |
| Reid, AY | 1 |
| Gaddam, M | 1 |
| Velagapudi, RK | 1 |
| Abu Sitta, E | 1 |
| Kanzy, A | 1 |
| Verma, T | 1 |
| Mallik, SB | 1 |
| Ramalingayya, GV | 1 |
| Nayak, PG | 1 |
| Kishore, A | 1 |
| Pai, KSR | 1 |
| Nandakumar, K | 1 |
| Dautzenberg, G | 1 |
| Nederlof, M | 1 |
| Beekman, A | 1 |
| Egberts, T | 1 |
| Heerdink, ER | 1 |
| Morris, JK | 1 |
| Garne, E | 1 |
| Loane, M | 1 |
| Addor, MC | 1 |
| Barisic, I | 1 |
| Bianchi, F | 1 |
| Gatt, M | 1 |
| Lanzoni, M | 1 |
| Lynch, C | 1 |
| Mokoroa, O | 1 |
| Nelen, V | 1 |
| Neville, A | 1 |
| O'Mahony, MT | 1 |
| Randrianaivo-Ranjatoelina, H | 1 |
| Rissmann, A | 1 |
| Tucker, D | 1 |
| de Walle, HEK | 1 |
| Zymak-Zakutnia, N | 1 |
| Rankin, J | 1 |
| Okumura, A | 1 |
| Kurahashi, H | 1 |
| Iwayama, H | 1 |
| Numoto, S | 1 |
| Wang, MJ | 1 |
| Jiang, L | 1 |
| Chen, HS | 1 |
| Cheng, L | 1 |
| Ishii, N | 1 |
| Terao, T | 1 |
| Araki, Y | 1 |
| Hatano, K | 1 |
| Thomas, KL | 1 |
| La, AQ | 1 |
| Punia, S | 1 |
| Doroudgar, S | 1 |
| Perry, PJ | 1 |
1 review available for valproic acid and Cognitive Decline
| Article | Year |
|---|---|
A focus on valproate and cognitive deficits in Bipolar Disorders: A mini-review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD.
Topics: Adult; Affect; Antimanic Agents; Bipolar Disorder; Cognitive Dysfunction; Cross-Sectional Studies; F | 2020 |
1 trial available for valproic acid and Cognitive Decline
| Article | Year |
|---|---|
Randomized controlled trial of adjunctive Valproate for cognitive remediation in early course schizophrenia.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Cognitive Dysfunction; Double-Blind Metho | 2019 |
21 other studies available for valproic acid and Cognitive Decline
| Article | Year |
|---|---|
HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY.
Topics: Ammonia; Anticonvulsants; Cognitive Dysfunction; Dementia; Epilepsy; Female; Humans; Hyperammonemia; | 2022 |
Lithium produces bi-directionally regulation of mood disturbance, acts synergistically with anti-depressive/-manic agents, and did not deteriorate the cognitive impairment in murine model of bipolar disorder.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cognitive Dysfu | 2022 |
Photobiomodulation Attenuated Cognitive Dysfunction and Neuroinflammation in a Prenatal Valproic Acid-Induced Autism Spectrum Disorder Mouse Model.
Topics: Animals; Autism Spectrum Disorder; Behavior, Animal; Cognitive Dysfunction; Disease Models, Animal; | 2022 |
Memantine/Aripiprazole Combination Alleviates Cognitive Dysfunction in Valproic Acid Rat Model of Autism: Hippocampal CREB/BDNF Signaling and Glutamate Homeostasis.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Brain-Derived Neurotrophic Facto | 2023 |
Amelioration of cognition impairments in the valproic acid-induced animal model of autism by ciproxifan, a histamine H3-receptor antagonist.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Cognition; Cognitive Dysfunc | 2023 |
Music alleviates cognitive impairments in an animal model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Cognitive Dysfunction; Disea | 2023 |
Three-year longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies; C | 2020 |
Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure.
Topics: Anticonvulsants; Carbamazepine; Child; Child Development; Cognitive Dysfunction; Female; Humans; Lam | 2020 |
Valproic acid treated female Long-Evans rats are impaired on attentional set-shifting.
Topics: Animals; Attention; Autism Spectrum Disorder; Behavior, Animal; Cognitive Dysfunction; Disease Model | 2021 |
Pharmacodynamic and pharmacokinetic interactions of hydroalcoholic leaf extract of Centella asiatica with valproate and phenytoin in experimental models of epilepsy in rats.
Topics: Adjuvants, Pharmaceutic; Animals; Anticonvulsants; Behavior, Animal; Centella; Cognitive Dysfunction | 2021 |
Sodium phenylbutyrate reduces repetitive self-grooming behavior and rescues social and cognitive deficits in mouse models of autism.
Topics: Animals; Antineoplastic Agents; Autism Spectrum Disorder; Brain; Cognitive Dysfunction; Disease Mode | 2021 |
Pergularia daemia hydro-ethanolic extract protects against pentylenetetrazole kindling-induced seizures, oxidative stress, and neuroinflammation in mice.
Topics: Animals; Anti-Inflammatory Agents; Anticonvulsants; Antioxidants; Apocynaceae; Cameroon; Cognitive D | 2021 |
Post-Traumatic Epilepsy in Zebrafish Is Drug-Resistant and Impairs Cognitive Function.
Topics: Animals; Anticonvulsants; Carbamazepine; Cognitive Dysfunction; Disease Models, Animal; Drug Resista | 2021 |
Two gaps too many, three clues too few? Do elevated osmolal and anion gaps with crystalluria always mean ethylene glycol poisoning?
Topics: Acid-Base Equilibrium; Acidosis; Anticonvulsants; Brain Diseases; Calcium Oxalate; Cognitive Dysfunc | 2017 |
Sodium valproate enhances doxorubicin-induced cognitive dysfunction in Wistar rats.
Topics: Acetylation; Animals; Brain; Cognitive Dysfunction; Doxorubicin; Histone Deacetylase Inhibitors; His | 2017 |
Severe Cognitive Impairment Associated With a High Free But Therapeutic Total Concentration of Valproic Acid Due to Hypoalbuminemia in an Older Patient With Bipolar Disorder.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Cognitive Dysfunction; Female; Humans; Hypoalbuminemia; Pr | 2018 |
Prevalence of valproate syndrome in Europe from 2005 to 2014: A registry based multi-centre study.
Topics: Adult; Anticonvulsants; Cognitive Dysfunction; Congenital Abnormalities; Epilepsy; Europe; Female; H | 2018 |
Serum carnitine levels of children with epilepsy: Related factors including valproate.
Topics: Adolescent; Body Mass Index; Carnitine; Child; Child, Preschool; Cognitive Dysfunction; Epilepsy; Fe | 2019 |
Levetiracetam Protects Against Cognitive Impairment of Subthreshold Convulsant Discharge Model Rats by Activating Protein Kinase C (PKC)-Growth-Associated Protein 43 (GAP-43)-Calmodulin-Dependent Protein Kinase (CaMK) Signal Transduction Pathway.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cognitive Dysfunction; Disease Models, Animal | 2019 |
Repeated seizures in an elderly patient with alcohol dependence and mild cognitive impairment.
Topics: Aged; Alcohol Withdrawal Seizures; Alcoholism; Cognitive Dysfunction; Diazepam; Humans; Male; Valpro | 2013 |
Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients.
Topics: Adult; Antimanic Agents; Cognitive Dysfunction; Female; Hepatic Encephalopathy; Humans; Hyperammonem | 2016 |